| 描述 |
Colestilan(MCI-196)是一种非吸收性、非钙基磷酸盐粘合剂,也是一种非金属阴离子交换树脂。科尔斯蒂兰具有口服活性,可用于高胆固醇血症研究[1][2]。
|
| 相关类别 |
|
| 体外研究 |
Colestilan(MCI-196)通过胃肠道胆汁酸吸附降低胆固醇水平[2]。科尔斯蒂兰(1克)结合2.52 2–4毫摩尔磷酸盐 mM磷酸盐浓度和pH7.2体外[2]。
|
| 体内研究 |
Colestilan(MCI-196)(每15克饲料含0.125或0.5克；14天)可降低大鼠的血磷和尿磷排泄[3]。考来司坦能够改善腺嘌呤给药4周诱导的肾衰竭大鼠的高磷血症[1]。动物模型：6周龄Wistar雄性大鼠[3]剂量：0.125或0.5 g含量/15 g饲料给药：口服饲料,14天结果：剂量依赖性降低血磷和尿磷排泄。
|
| 参考文献 |
[1]. Locatelli F, et al. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant. 2010 Feb;25(2):574-81. [2]. Kurihara S, et al. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplant. 2005 Feb;20(2):424-30. [3]. MATSUKA MASAYUKI, et al. Use of anion exchange resins for the manufacture of a medicament for the treatment of hyperphosphatemia. Patent EP0793960.
|
